GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultimovacs ASA (STU:7UM) » Definitions » EV-to-FCF

Ultimovacs ASA (STU:7UM) EV-to-FCF : -0.18 (As of May. 21, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Ultimovacs ASA EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Ultimovacs ASA's Enterprise Value is €3.06 Mil. Ultimovacs ASA's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was €-17.32 Mil. Therefore, Ultimovacs ASA's EV-to-FCF for today is -0.18.

The historical rank and industry rank for Ultimovacs ASA's EV-to-FCF or its related term are showing as below:

STU:7UM' s EV-to-FCF Range Over the Past 10 Years
Min: -24.98   Med: 0   Max: 0.24
Current: -0.18

During the past 9 years, the highest EV-to-FCF of Ultimovacs ASA was 0.24. The lowest was -24.98. And the median was 0.00.

STU:7UM's EV-to-FCF is ranked worse than
100% of 379 companies
in the Biotechnology industry
Industry Median: 8.34 vs STU:7UM: -0.18

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-21), Ultimovacs ASA's stock price is €0.568. Ultimovacs ASA's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €-0.451. Therefore, Ultimovacs ASA's PE Ratio for today is At Loss.


Ultimovacs ASA EV-to-FCF Historical Data

The historical data trend for Ultimovacs ASA's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ultimovacs ASA EV-to-FCF Chart

Ultimovacs ASA Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only -11.02 -18.71 -26.11 -20.04 -20.87

Ultimovacs ASA Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -23.25 -12.19 -16.05 -20.87 -0.28

Competitive Comparison of Ultimovacs ASA's EV-to-FCF

For the Biotechnology subindustry, Ultimovacs ASA's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ultimovacs ASA's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ultimovacs ASA's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Ultimovacs ASA's EV-to-FCF falls into.



Ultimovacs ASA EV-to-FCF Calculation

Ultimovacs ASA's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=3.062/-17.32
=-0.18

Ultimovacs ASA's current Enterprise Value is €3.06 Mil.
Ultimovacs ASA's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-17.32 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ultimovacs ASA  (STU:7UM) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Ultimovacs ASA's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.568/-0.451
=At Loss

Ultimovacs ASA's share price for today is €0.568.
Ultimovacs ASA's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.451.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Ultimovacs ASA EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Ultimovacs ASA's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Ultimovacs ASA (STU:7UM) Business Description

Traded in Other Exchanges
Address
Ullernchausseen 64, Oslo, NOR, 0379
Ultimovacs ASA is a pharmaceutical company involved in developing novel immunotherapies against cancer. Its product candidate is UV1, a peptide-based vaccine inducing T cell responses against the universal cancer antigen telomerase. The company and its proprietary technology are based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital.

Ultimovacs ASA (STU:7UM) Headlines

No Headlines